Valuation: argenx SE

Market Cap 51.97B 45.16B 42.17B 38.71B 72.99B 4,953B 74.26B 497B 195B 2,470B 195B 191B 8,147B P/E 2026 *
30.4x
P/E 2027 * 24.5x
Enterprise Value 46.61B 40.51B 37.82B 34.72B 65.46B 4,442B 66.6B 446B 175B 2,215B 175B 171B 7,307B EV / Sales 2026 *
7.55x
EV / Sales 2027 * 5.84x
Free-Float
99.98%
Yield 2026 *
0.05%
Yield 2027 * 0.1%
1 day+0.66%
1 week-5.83%
Current month-2.42%
1 month-10.58%
3 months+6.22%
6 months+1.31%
Current year+1.42%
1 week 717.4
Extreme 717.4
778.6
1 month 717.4
Extreme 717.4
832
Current year 568.4
Extreme 568.4
833.6
1 year 544.2
Extreme 544.2
833.6
3 years 271
Extreme 271
833.6
5 years 224.1
Extreme 224.1
833.6
10 years 12.5
Extreme 12.5
833.6
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
+0.53%-5.83%+23.72%+62.42% 51.97B
+0.05%+3.08%+38.17%+66.77% 56.7B
-0.38%+1.27%-14.06%-13.50% 23.33B
-0.18%-6.00%-9.42%+344.47% 21.34B
+2.15%-0.71%+33.98%-25.15% 17.44B
+9.91%-2.51%+188.84%+326.19% 14.77B
+0.27%-1.34%+47.77%+165.22% 13.84B
+2.03%+0.56%+439.92%+166.12% 12.12B
+3.91%-12.56%+59.51%+149.39% 11.14B
+0.82%-5.17%+108.37%+141.17% 10.38B
Average +1.93%-2.61%+91.68%+138.31% 23.3B
Weighted average by Cap. +1.24%-2.09%+60.21%+111.04%

Financials

2026 *2027 *
Net sales 6.18B 5.37B 5.01B 4.6B 8.68B 589B 8.83B 59.09B 23.14B 294B 23.2B 22.69B 968B 7.58B 6.59B 6.15B 5.65B 10.65B 722B 10.83B 72.52B 28.4B 360B 28.47B 27.84B 1,188B
Net income 1.84B 1.6B 1.49B 1.37B 2.58B 175B 2.62B 17.57B 6.88B 87.31B 6.9B 6.75B 288B 2.44B 2.12B 1.98B 1.82B 3.43B 233B 3.49B 23.35B 9.15B 116B 9.17B 8.97B 383B
Net Debt -5.36B -4.66B -4.35B -3.99B -7.53B -511B -7.66B -51.29B -20.09B -255B -20.14B -19.69B -840B -7.74B -6.73B -6.28B -5.77B -10.87B -738B -11.06B -74.05B -29B -368B -29.07B -28.43B -1,214B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-04 726.00 +0.53% 25,394
26-08-03 €722.20 -3.06% 94,348
26-07-31 €745.00 -0.21% 96,817
26-07-30 €746.60 -3.74% 97,191
26-07-29 €775.60 +0.47% 72,563
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
830.97USD
Average target price
1,032.12USD
Spread / Average Target
+24.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock